Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8385573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma

  2004cited by this paper
• Macrophage infiltration and tumor progression

  2004cited by this paper
• Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.

  1993cited by this paper
• The origin and function of tumor-associated macrophages.

  1992cited by this paper
• Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.

  1992cited by this paper
• cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator.

  1992cited by this paper
• Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.

  1992cited by this paper
• The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.

  1992cited by this paper
• Identification of type I collagen-producing cells in human gastrointestinal carcinomas by non-radioactive in situ hybridization and immunoelectron microscopy.

  1992cited by this paper
• Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2.

  1992cited by this paper
• Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor

  1991cited by this paper
• Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours

  1991cited by this paper
• Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator

  1991cited by this paper
• Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization.

  1991cited by this paper
• Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

  1991cited by this paper
• Plasminogen Activation by Receptor-Bound Urokinase

  1991cited by this paper
• Urokinase‐receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.

  1991cited by this paper
• Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

  1991cited by this paper
• In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion

  1991cited by this paper
• The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.

  1991cited by this paper
• Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

  1990cited by this paper
• Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

  1990cited by this paper
• Urokinase receptors in human monocytes.

  1990cited by this paper
• The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

  1990cited by this paper
• A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

  1990cited by this paper
• Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer

  1990cited by this paper
• Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system

  1990cited by this paper
• One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.

  1988cited by this paper
• In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase

  1988cited by this paper
• Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.

  1988cited by this paper
• Cell-associated plasminogen activation: regulation and physiological functions.

  1988cited by this paper
• A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.

  1988cited by this paper
• Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors

  1987cited by this paper
• Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.

  1986cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

  1985cited by this paper
• Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

  1985cited by this paper
• immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma

  1984cited by this paper
• The use of avidin-biotin interaction in immunoenzymatic techniques.

  1979cited by this paper
• A better cell line for making hybridomas secreting specific antibodies

  1978cited by this paper
• ACTIVATION OF PLASMINOGEN: A GENERAL MECHANISM FOR PRODUCING LOCALIZED EXTRACELLULAR PROTEOLYSIS

  1978cited by this paper

• Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity

  2025cites this paper
• Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted.

  2024cites this paper
• uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review).

  2022cites this paper
• Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy

  2021cites this paper
• Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma

  2021cites this paper
• The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

  2021cites this paper
• Molecular imaging of proteases in cancer

  2020cites this paper
• Stromal Markers of Breast Cancer Progression: A Review of Recent Findings

  2019cites this paper
• The Role of Stromal Proteolytic Systems in Cancer Progression (Review)

  2019cites this paper
• Diversity and functional evolution of the plasminogen activator system.

  2018cites this paper
• The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer

  2018cites this paper
• Proteases as prognostic markers in human and canine cancers

  2017cites this paper
• Diverse Applications of Nanomedicine

  2017cites this paper
• Urokinase Plasminogen Activator Receptor-PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.

  2017cites this paper
• Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer

  2016cites this paper
• Oligonucleotide-based theranostic nanoparticles in cancer therapy.

  2016cites this paper
• Oral Squamous Cell Carcinoma - Role of the Plasminogen Activation System in Tumour Progression.

  2015cites this paper
• Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR

  2015cites this paper
• Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.

  2015cites this paper
• CROSS-TALK BETWEEN THE PROTEOLYTIC AND NON-PROTEOLYTIC FUNCTIONS OF THE UROKINASE RECEPTOR

  2015cites this paper
• Molecular Imaging with MRI: Potential Application in Pancreatic Cancer

  2015cites this paper
• Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance

  2014cites this paper
• uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.

  2014cites this paper
• The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small cell lung cancer

  2013cites this paper
• The Requirement for Oxygen in the Maturation and Secretion of Soluble urokinase Plasminogen Activator Receptor (uPAR)

  2013cites this paper
• uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection

  2013cites this paper
• Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical

  2013cites this paper
• Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications

  2013cites this paper
• Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles.

  2013cites this paper
• Tumor Associated Macrophages-Friends Turned Foe? A Case Report And Review Of Literature

  2012cites this paper
• Plasminogen Activators and Their Inhibitors in Cancer

  2012cites this paper
• Tumor Associated Macrophages-Friends Turned Foe? A Case Report And Review Of Literature.

  2012cites this paper
• Development of targeted anticancer agents using novel N-alkylisatin derivatives

  2012cites this paper
• A deficiency of uPAR alters endothelial angiogenic function and cell morphology

  2011cites this paper
• The Angiogenic Switch: Role of Immune Cells

  2011cites this paper
• THE NK CELLS PHENOTYPE AND FUNCTION IN RESECTED NON SMALL CELL LUNG CANCER: DIFFERENCES BETWEEN SQUAMOUS AND ADENOCARCINOMA AND RELATION TO TUMOR ANGIOGENESIS

  2011cites this paper
• Urokinase Plasminogen Activator Receptor in Adipose Tissue Macrophages of Morbidly Obese Subjects

  2011cites this paper
• uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.

  2011cites this paper
• ROLE OF VITRONECTIN INTERACTION IN THE BIOLOGY OF THE UROKINASE RECEPTOR

  2011cites this paper
• Functional in vitro analyses of lipid raft-associated cathepsin b: implication for the invasive phenotype of inflammatory breast cancer

  2011cites this paper
• Clinical applications of the urokinase receptor (uPAR) for cancer patients.

  2011cites this paper
• A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.

  2010cites this paper
• A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis

  2010cites this paper
• Prognostic relevance of tumour cell‐associated uPAR expression in invasive ductal breast carcinoma

  2010influential citation
• System in Tumor Invasion

  2010cites this paper
• Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.

  2009cites this paper
• Tumor-Associated Macrophage Correlated with Angiogenesis and Progression of Mucoepidermoid Carcinoma of Salivary Glands

  2009cites this paper
• Quantification of Urokinase Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 (PAI-1) mRNA in Breast Cancer Tissue

  2009cites this paper
• Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases

  2009cites this paper
• The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

  2009cites this paper
• The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.

  2008cites this paper
• The Plasminogen Activation System as a Source of Prognostic Markers in Cancer

  2008cites this paper
• Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma.

  2008cites this paper
• Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases

  2008cites this paper
• Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy‐refractory diffuse large B‐cell lymphoma

  2008cites this paper
• Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.

  2008cites this paper
• Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.

  2008cites this paper
• The urokinase receptor and integrins in cancer progression

  2008cites this paper
• Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.

  2008cites this paper
• Extracellular Proteolysis in Transgenic Mouse Models of Breast Cancer

  2007cites this paper
• Deciphering the molecular basis of breast cancer metastasis with mouse models

  2007cites this paper
• Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptormediated uPA activity in vitro and in vivo

  2007cites this paper
• Comparative Genomics on the Basal Mammalian Urokinase Receptor-Promoter and Impact for Potential in Vivo/Clinical Relevance in Cancer

  2007cites this paper
• Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor

  2007cites this paper
• Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.

  2007cites this paper
• Urokinase receptor variants in tissue and body fluids.

  2007cites this paper
• Antitumor efficacy of a urokinase activation–dependent anthrax toxin

  2006cites this paper
• Targeting urokinase-type plasminogen activator and its receptor for cancer therapy

  2006cites this paper
• Expression of plasminogen activator inhibitor‐1, urokinase receptor and laminin γ‐2 chain is an early coordinated event in incipient oral squamous cell carcinoma

  2006cites this paper
• Plasminogen activation and cancer

  2005cites this paper
• Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma

  2005cites this paper
• Macrophages promote angiogenesis in human breast tumour spheroids in vivo

  2005cites this paper
• Urokinase-type plasminogen activator system and breast cancer (Review).

  2005cites this paper
• Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue

  2005cites this paper
• Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.

  2005cites this paper
• Reduced metastasis of transgenic mammary cancer in urokinase‐deficient mice

  2005cites this paper
• Tumor invasion, proteolysis, and angiogenesis

  2005cites this paper
• Breast cancer prognostic and predictive factors

  2004cites this paper
• Matrix-degrading proteases in hormone-dependent breast cancer

  2004cites this paper
• The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/ Endo180): membrane proteins engaged in matrix turnover during tissue remodeling

  2004cites this paper
• Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer

  2004cites this paper
• Interplay between inflammation and tumor angiogenesis

  2004cites this paper
• A central role for plasminogen in the inflammatory response to biomaterials

  2004cites this paper
• Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns

  2004cites this paper
• Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism

  2004cites this paper
• Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy

  2004cites this paper
• The urokinase receptor as a potential target in cancer therapy.

  2004cites this paper
• Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells

  2003cites this paper
• Proteolysis in Carcinogenesis

  2003cites this paper
• Stromal cell involvement in cancer.

  2003cites this paper
• Expression der Proteinasen Urokinase Plasminogen Aktivator (uPA), dessen Gewebe Typ (tPA) und Inhibitor Plasminogen Aktivator Inhibitor Typ 1 (PAI-1) in gutartigen und bösartigen Erkrankungen der weiblichen Brustdrüse

  2003cites this paper
• Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice

  2003cites this paper
• Molecular targets in breast cancer: current status and future directions.

  2002cites this paper
• Inhibitors of the protease domain of urokinase-type plasminogen activator.

  2002cites this paper
• New insights into the role of extracellular matrix during tumor onset and progression

  2002cites this paper
• Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

  2002cites this paper
• Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages

  2002cites this paper
• UROKINAS ERECEPTOR-ASSOCIATE DPROTEI N(UPARAP )I SEXPRESSED I NCONNECTIO NWIT HMALIGNAN TA SWEL LA SBENIG NLESIONS O FTH EHUMA NBREAS TAN DOCCUR SI NSPECIFI CPOPULATIONS O FSTROMA LCELLS

  2002cites this paper
• Tumor-Associated Macrophages in Breast Cancer

  2002cites this paper
• Urokinase receptor‐associated protein (UPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells

  2002cites this paper